Aurobindo Pharma Ltd has received approval for Cefuroxime Axetil Tablets USP, 125 mg (base), 250 mg (base), 500 mg (base) from US FDA

With this Oral Cephalosporin approval, the company's product basket for the US market has increased to 13 (Final approvals). Apart from this, the company has 10 tentative approvals for the US market, stated a release.
The size of generics business of Cefuroxime Axetil 125 / 250 / 500 mg is around USD 50 million.

Cefuroxime Axetil tablets are indicated for the treatment of patients with infections caused by susceptible strains of designated organisms in the diseases include: Pharyngitis and Tonsillitis, Lower Respiratory Tract Infections, Urinary Tract Infections and Skin Structure Infections.

Cefuroxime Axetil Tablets USP, 125 mg (base), 250 mg (base), 500 mg (base) is the generic version of Glaxo Wellcome's Ceftin.

Meanwhile, Aurobindo Pharma Ltd has informed BSE that the board of directors of the company has considered and approved the proposal to issue Foreign Currency Convertible Bonds (FCCBs) up to USD 200 million in overseas markets to fund amongst other things, the overseas acquisitions and future growth requirements of the company.